Drug R&D Services Leader Implements A Collaborative Enterprise ELN To Advance Research

This BIOVIA customer has offered industry-leading drug discovery and development services for over 25 years. Its success lies in its fully integrated, holistic approach to small molecule drug discovery, spanning from target identification to investigational new drug (IND) submissions. The company has global research operations at five sites, with each site specializing in one part of the drug R&D value chain. Central operations, screening services, and in vitro and in vivo biological studies are conducted at one site; medicinal chemistry services, computational chemistry, structural biology, and DMPK studies are based in another; and additional medicinal chemistry support and library management and services occur elsewhere.

In a demanding and increasingly distributed research environment, drug discovery alliance companies can only attract and maintain collaborations by being responsive and providing high quality results as quickly as possible.

What mattered to this BIOVIA customer in meeting collaboration demands, however, was being able to rapidly collect together project information to deliver reports and data, fulfill patent submissions, or leverage and build on past work.